Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA.

Staphylococcus aureus bacteremia (SAB) is an urgent medical problem due to its growing frequency and its poor associated outcome. As healthcare delivery increasingly involves invasive procedures and implantable devices, the number of patients at risk for SAB and its complications is likely to grow. Compounding this problem is the growing prevalence of methicillin-resistant S. aureus (MRSA) and the dwindling efficacy of vancomycin, long the treatment of choice for this pathogen. Despite the recent availability of several new antibiotics for S. aureus, new strategies for treatment and prevention are required for this serious, common cause of human infection.

[1]  R Scott Obach,et al.  Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism , 2011, Journal of clinical pharmacology.

[2]  C. Vandenbroucke-Grauls,et al.  Prevalence of Methicillin-Resistant Staphylococcus aureus and Risk Factors for Carriage in Dutch Hospitals , 2010, Infection Control & Hospital Epidemiology.

[3]  F. Martínez Sagasti,et al.  Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. , 2010, JAMA.

[4]  J. Potts,et al.  Staphylococcus aureus Host Cell Invasion and Virulence in Sepsis Is Facilitated by the Multiple Repeats within FnBPA , 2010, PLoS pathogens.

[5]  F. DeLeo,et al.  Community-associated meticillin-resistant Staphylococcus aureus , 2010, The Lancet.

[6]  Gracia Morales,et al.  Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  W. van Pelt,et al.  Prevalence of Livestock-Associated MRSA in Communities with High Pig-Densities in The Netherlands , 2010, PloS one.

[8]  Walter R Wilson,et al.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. , 2010, Circulation.

[9]  S. Bentley,et al.  Evolution of MRSA During Hospital Transmission and Intercontinental Spread , 2010, Science.

[10]  Arthur J. L. Cooper,et al.  Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Daskalaki,et al.  Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? , 2010, The Journal of infectious diseases.

[12]  Paul D. R. Johnson,et al.  Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.

[13]  A. MacGowan,et al.  Future treatment options for Gram-positive infections--looking ahead. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  D. Nicolau,et al.  Newer developments in the treatment of Gram-positive infections , 2009, Expert opinion on pharmacotherapy.

[15]  C. Woods,et al.  Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. , 2009, The Journal of infectious diseases.

[16]  H. Seifert,et al.  Mortality of S. aureus bacteremia and infectious diseases specialist consultation--a study of 521 patients in Germany. , 2009, The Journal of infection.

[17]  G. Corey,et al.  New treatments for methicillin-resistant Staphylococcus aureus , 2009, Current opinion in critical care.

[18]  S. Kapetanakis,et al.  The Potential Impact of Contemporary Transthoracic Echocardiography on the Management of Patients with Native Valve Endocarditis: A Comparison with Transesophageal Echocardiography , 2009, Echocardiography.

[19]  C. Hassager,et al.  Major Cerebral Events in Staphylococcus Aureus Infective Endocarditis: Is Anticoagulant Therapy Safe? , 2009, Cardiology.

[20]  P. Viale,et al.  Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  N. Day,et al.  Factors Predicting and Reducing Mortality in Patients with Invasive Staphylococcus aureus Disease in a Developing Country , 2009, PloS one.

[22]  N. Kim,et al.  Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Ronald N. Jones,et al.  Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006 , 2009, Antimicrobial Agents and Chemotherapy.

[24]  I. Raad,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  C. Tascini,et al.  Linezolid Treatment for Gram-Positive Infections: A Retrospective Comparison with Teicoplanin , 2009, Journal of chemotherapy.

[26]  G. Corey,et al.  Staphylococcus aureus bloodstream infections: definitions and treatment. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Gilbert Habib,et al.  Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. , 2009, Annals of internal medicine.

[28]  J. Paul,et al.  Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  G. Rahav,et al.  Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. , 2009, The Journal of infectious diseases.

[30]  F. Vandenesch,et al.  Serum antibodies against Panton-Valentine leukocidin in a normal population and during Staphylococcus aureus infection. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  T. West,et al.  Staphylococcus aureus Bacteraemia in a Tropical Setting: Patient Outcome and Impact of Antibiotic Resistance , 2009, PloS one.

[32]  D. Herr,et al.  Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  V. Fowler,et al.  Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. , 2009, The Journal of infectious diseases.

[34]  B. Goldstein,et al.  Pharmacokinetic‐Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic , 2008, Journal of clinical pharmacology.

[35]  M. Beuran,et al.  Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. , 2008, The Journal of antimicrobial chemotherapy.

[36]  Hua-Hao Shen,et al.  Linezolid for the treatment of infections caused by Gram-positive pathogens in China. , 2008, International journal of antimicrobial agents.

[37]  K. Laupland,et al.  Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. , 2008, The Journal of infectious diseases.

[38]  C. Liao,et al.  Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an emergency department of a medical centre in Taiwan , 2008, International Journal of Antimicrobial Agents.

[39]  C. Woods,et al.  Associations between the Genotypes of Staphylococcus aureus Bloodstream Isolates and Clinical Characteristics and Outcomes of Bacteremic Patients , 2008, Journal of Clinical Microbiology.

[40]  K. Stellrecht,et al.  Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin , 2008, Antimicrobial Agents and Chemotherapy.

[41]  S. Nielsen,et al.  High risk for nasal carriage of methicillin-resistant Staphylococcus aureus among Danish veterinary practitioners. , 2008, Scandinavian journal of work, environment & health.

[42]  V. Fowler,et al.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Fred C Tenover,et al.  Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. , 2008, The Journal of infectious diseases.

[44]  I. Gould.  Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. , 2008, International journal of antimicrobial agents.

[45]  K. Bush,et al.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  G. Sensabaugh,et al.  Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus Clone USA300 in Men Who Have Sex with Men , 2008, Annals of Internal Medicine.

[47]  Á. Soriano,et al.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Mamta Sharma,et al.  Staphylococcus aureus skin/soft-tissue infections: The impact of SCCmec type and Panton-Valentine leukocidin , 2008, Scandinavian journal of infectious diseases.

[49]  C. Nelson,et al.  Genotypic Characteristics of Staphylococcus aureus Isolates from a Multinational Trial of Complicated Skin and Skin Structure Infections , 2007, Journal of Clinical Microbiology.

[50]  P. Appelbaum.  Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). , 2007, International journal of antimicrobial agents.

[51]  W. Suki,et al.  Early-onset rhabdomyolysis related to daptomycin use. , 2007, International journal of antimicrobial agents.

[52]  A. van Belkum,et al.  Overlapping Population Structures of Nasal Isolates of Staphylococcus aureus from Healthy Dutch and American Individuals , 2007, Journal of Clinical Microbiology.

[53]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[54]  M. Herregods,et al.  Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. , 2007, Mayo Clinic proceedings.

[55]  L. Friedrich,et al.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.

[56]  C. Nelson,et al.  Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. , 2007, The Journal of infectious diseases.

[57]  G. Talbot,et al.  Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections , 2007, Antimicrobial Agents and Chemotherapy.

[58]  R. Daum.  Skin and Soft-Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus , 2007 .

[59]  Alexander Tomasz,et al.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing , 2007, Proceedings of the National Academy of Sciences.

[60]  David L Hayes,et al.  Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. , 2007, Journal of the American College of Cardiology.

[61]  T. Foster,et al.  Both Complement- and Fibrinogen-Dependent Mechanisms Contribute to Platelet Aggregation Mediated by Staphylococcus aureus Clumping Factor B , 2007, Infection and Immunity.

[62]  David L Hayes,et al.  Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. , 2007, Archives of internal medicine.

[63]  G. Rahav,et al.  Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care Center , 2007, Journal of Clinical Microbiology.

[64]  A. Jensen,et al.  Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[65]  E. Delong,et al.  Staphylococcus aureus Panton-Valentine Leukocidin Causes Necrotizing Pneumonia , 2007, Science.

[66]  L. Szczech,et al.  Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  Guiqing Wang,et al.  Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period , 2006, Journal of Clinical Microbiology.

[68]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[69]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[70]  G. Stein,et al.  Tigecycline: a critical analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  S. Saba,et al.  Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. , 2006, Journal of the American College of Cardiology.

[72]  Joshua A. Doherty,et al.  Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment* , 2006, Critical care medicine.

[73]  D. Paterson,et al.  Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  B. Murphy,et al.  Rhabdomyolysis during therapy with daptomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  J. Patel,et al.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  A. van Belkum,et al.  Distribution of the Serine-Aspartate Repeat Protein-Encoding sdr Genes among Nasal-Carriage and Invasive Staphylococcus aureus Strains , 2006, Journal of Clinical Microbiology.

[77]  V. Fowler,et al.  Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study , 2006, Antimicrobial Agents and Chemotherapy.

[78]  L. Cui,et al.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[79]  G. Martinelli,et al.  Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  D. Sahm,et al.  Annals of Clinical Microbiology and Antimicrobials Laboratory-based Surveillance of Current Antimicrobial Resistance Patterns and Trends among Staphylococcus Aureus: 2005 Status in the United States , 2022 .

[81]  N. Day,et al.  Meticillin-resistant Staphylococcus aureus in rural Asia. , 2006, The Lancet. Infectious diseases.

[82]  J. Timsit,et al.  Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  J. Patel,et al.  Characterization of a Strain of Community-AssociatedMethicillin-Resistant Staphylococcus aureus WidelyDisseminated in the UnitedStates , 2006, Journal of Clinical Microbiology.

[84]  R. Murray.  Recognition and management of Staphylococcus aureus toxin‐mediated disease , 2005, Internal medicine journal.

[85]  K. Schulman,et al.  Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. , 2005, The American journal of medicine.

[86]  E. Loh,et al.  The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  E. Loh,et al.  Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. , 2005, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[88]  Bruno Hoen,et al.  Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  J. Weber.  Community-associated methicillin-resistant Staphylococcus aureus. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  K. Anstrom,et al.  Staphylococcus aureus endocarditis: a consequence of medical progress. , 2005, JAMA.

[91]  L. Mortin,et al.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. , 2005, The Journal of infectious diseases.

[92]  A. Järvinen,et al.  Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995–2001 , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[93]  V. Fowler,et al.  Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. , 2005, The American journal of medicine.

[94]  Arjun Srinivasan,et al.  A clone of methicillin-resistant Staphylococcus aureus among professional football players. , 2005, The New England journal of medicine.

[95]  B. Goldstein,et al.  Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  S. Hopkins,et al.  Healthcare-Associated Staphylococcus aureus Bacteremia and the Risk for Methicillin Resistance: Is the Centers for Disease Control and Prevention Definition for Community-Acquired Bacteremia Still Appropriate? , 2005, Infection Control & Hospital Epidemiology.

[97]  M. Moorhouse,et al.  Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. , 2004, The Journal of clinical investigation.

[98]  T. Foster.  The Staphylococcus aureus "superbug". , 2004, The Journal of clinical investigation.

[99]  M. Yalaz,et al.  Experience with Teicoplanin in the Treatment of Neonatal Staphylococcal Sepsis , 2004, The Journal of international medical research.

[100]  Ronald N. Jones,et al.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). , 2004, Diagnostic microbiology and infectious disease.

[101]  H. Wertheim,et al.  Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers , 2004, The Lancet.

[102]  G. Eliopoulos,et al.  Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2004, Journal of Clinical Microbiology.

[103]  M. Vergassola,et al.  DNA Macroarray for Identification and Typing of Staphylococcus aureus Isolates , 2004, Journal of Clinical Microbiology.

[104]  J. Lamar,et al.  Community-acquired Methicillin-resistant Staphylococcus aureus among Military Recruits , 2004, Emerging infectious diseases.

[105]  S. Lerakis,et al.  Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. , 2004, American heart journal.

[106]  D. Nathwani,et al.  Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. , 2004, The Journal of antimicrobial chemotherapy.

[107]  P. Ward,et al.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[108]  D. Robinson,et al.  Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[109]  Susan K. Johnson,et al.  Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. , 2003, JAMA.

[110]  G. Sensabaugh,et al.  Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[111]  S. McAllister,et al.  Pulsed-Field Gel Electrophoresis Typing of Oxacillin-Resistant Staphylococcus aureus Isolates from the United States: Establishing a National Database , 2003, Journal of Clinical Microbiology.

[112]  C. Woods,et al.  Clinical identifiers of complicated Staphylococcus aureus bacteremia. , 2003, Archives of internal medicine.

[113]  Patricia F Triplett,et al.  A Prospective Multicenter Study of Staphylococcus aureus Bacteremia: Incidence of Endocarditis, Risk Factors for Mortality, and Clinical Impact of Methicillin Resistance , 2003, Medicine.

[114]  Patricia F Triplett,et al.  Staphylococcus aureus Bacteremia: Recurrence and the Impact of Antibiotic Treatment in a Prospective Multicenter Study , 2003, Medicine.

[115]  H. Shapiro,et al.  Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.

[116]  B. Spratt,et al.  How Clonal Is Staphylococcus aureus? , 2003, Journal of bacteriology.

[117]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[118]  N. Day,et al.  Virulent Combinations of Adhesin and Toxin Genes in Natural Populations of Staphylococcus aureus , 2002, Infection and Immunity.

[119]  L. John,et al.  Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections , 2002 .

[120]  D. Fitzgerald,et al.  Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine–aspartate repeat protein SdrE and protein A , 2002, Molecular microbiology.

[121]  P. Vanhems,et al.  Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients , 2002, The Lancet.

[122]  R. Darouiche.  Device-associated infections: a macroproblem that starts with microadherence. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  Amy V. Groom,et al.  Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. , 2001, JAMA.

[124]  Vance G. Fowler,et al.  Staphylococcus aureus Bacteremia in Patients With Permanent Pacemakers or Implantable Cardioverter-Defibrillators , 2001, Circulation.

[125]  Mary Jane Ferraro,et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.

[126]  H Stammer,et al.  Nasal Carriage as a Source of Staphylococcus aureus Bacteremia , 2001 .

[127]  K. Krause,et al.  Heterologously Expressed Staphylococcus aureusFibronectin-Binding Proteins Are Sufficient for Invasion of Host Cells , 2000, Infection and Immunity.

[128]  A. Jensen,et al.  Risk factors for hospital-acquired Staphylococcus aureus bacteremia. , 1999, Archives of internal medicine.

[129]  N. Frimodt-Møller,et al.  Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. , 1999, Archives of internal medicine.

[130]  G. Gottlieb,et al.  Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. , 1997, Journal of the American College of Cardiology.

[131]  R. Hershow,et al.  Retrospective Evaluation of Therapies for Staphylococcus aureus Endocarditis , 1997, Pharmacotherapy.

[132]  N. Frimodt-Møller,et al.  Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990. , 1997, Clinical Microbiology and Infection.

[133]  N Frimodt-Møller,et al.  Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. , 1997, The American journal of medicine.

[134]  L. Elting,et al.  A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. , 1994, The Journal of infectious diseases.

[135]  W J Martone,et al.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.

[136]  F. Meunier,et al.  Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts , 1991, Antimicrobial Agents and Chemotherapy.

[137]  W. Somerville,et al.  Prevention of Infective Endocarditis , 1981, Pediatrics.

[138]  A. van Belkum,et al.  Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[139]  P. Seferovic.  The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC) , 2009 .

[140]  M. Falagas,et al.  Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. , 2008, The Lancet. Infectious diseases.

[141]  P. Newton,et al.  Public health impact of establishing the cause of bacterial infections in rural Asia. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[142]  M. Falagas,et al.  Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections , 2008, Drug safety.

[143]  A. Bolmström,et al.  A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. , 2006, The Journal of antimicrobial chemotherapy.

[144]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[145]  M. Höök,et al.  MSCRAMM-mediated adherence of microorganisms to host tissues. , 1994, Annual review of microbiology.

[146]  P. Schlievert,et al.  Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. , 1990, Critical reviews in microbiology.